Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C.

PLoS One. 2012;7(12):e51862. doi: 10.1371/journal.pone.0051862. Epub 2012 Dec 14.

2.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
3.
4.

The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.

Hupperets PS, Volovics L, Schouten LJ, Jager JJ, Schouten HC, Hillen HF, Blijham GH.

Am J Clin Oncol. 1997 Dec;20(6):546-51.

PMID:
9391537
5.

Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.

Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF.

Breast Cancer Res Treat. 2003 Mar;78(2):193-204.

PMID:
12725419
6.

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31.

8.

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z.

Breast Cancer Res Treat. 2010 Oct;123(3):725-31. doi: 10.1007/s10549-009-0674-9. Epub 2009 Dec 18.

PMID:
20020197
9.

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.

Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R.

Diagn Pathol. 2012 Mar 22;7:31. doi: 10.1186/1746-1596-7-31.

11.

Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.

Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C.

Diagn Mol Pathol. 2011 Mar;20(1):1-10. doi: 10.1097/PDM.0b013e3181e3630c.

PMID:
21326033
12.

Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.

Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, Iyama K, Iwase H.

Mod Pathol. 2013 Jan;26(1):79-86. doi: 10.1038/modpathol.2012.151. Epub 2012 Aug 24.

13.
14.

Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.

Fuqua SA, Cui Y.

Breast Cancer Res Treat. 2004;87 Suppl 1:S3-10.

PMID:
15597215
15.

Molecular aspects of estrogen receptor variants in breast cancer.

Fuqua SA, Wolf DM.

Breast Cancer Res Treat. 1995 Sep;35(3):233-41. Review.

PMID:
7579493
16.

Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.

Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Syed Hussain SN.

Malays J Pathol. 2010 Dec;32(2):117-22.

17.

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.

Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM.

Breast Cancer Res. 2008;10(5):R89. doi: 10.1186/bcr2187. Epub 2008 Oct 23.

18.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

PMID:
19414985
19.
20.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139

Supplemental Content

Support Center